Talk:Olanzapine

From PsychonautWiki
(Redirected from Olanzapine)
Jump to navigation Jump to search
Summary sheet: Olanzapine
Olanzapine
Olanzapine.svg
Chemical Nomenclature
Common names Olanzapine, Zyprexa
Systematic name 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Class Membership
Psychoactive class Antipsychotic
Chemical class Thienobenzodiazepine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Bioavailability 60 - 65%[1]
Threshold 1 mg
Light 2.5 - 5 mg
Common 5 - 10 mg
Strong 10 - 15 mg
Heavy 15 mg +
Duration
Total 6 - 8 hours
Onset 40 - 60 minutes
Peak 1.5 - 6 hours
Offset 8 - 12 hours
After effects 20 - 24 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions

Olanzapine, first branded as Zyprexa, is a widely-used antipsychotic substance of the thienobenzodiazepine chemical class. It produces sedating and neuroleptic effects when administered. Olanzapine can be given by mouth and can also be injected into a muscle. Olanzapine might be useful as a trip aborter, especially for stimulants, as it blocks the action of dopamine. [citation needed]

Chemistry

Olanzapine is a thienobenzodiazepine. It includes a piperazine moiety at R4.

Pharmacology

Olanzapine is known to cause weight gain and induce diabetes mellitus type 2 more frequently than other antipsychotics. However, it is less likely to produce tardive dyskinesia or an extrapyramidal reaction. It appears to be an effective treatment for schizophrenia.[2]

Subjective effects

Physical effects
Child.svg

Cognitive effects
User.svg


Experience reports

There are currently 0 experience reports which describe the effects of this substance in our experience index.

Additional experience reports can be found here:

External links

References

  1. https://doi.org/10.2165%2F00003088-200746050-00001
  2. Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Örey, D., Richter, F., ... & Kissling, W. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet, 382(9896), 951-962.